BTIG Research Reaffirms “Buy” Rating for CeriBell (NASDAQ:CBLL)

CeriBell (NASDAQ:CBLL)‘s stock had its “buy” rating restated by BTIG Research in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $30.00 target price on the stock. BTIG Research’s target price would suggest a potential upside of 37.80% from the stock’s previous close.

A number of other analysts have also weighed in on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CeriBell in a research report on Wednesday, October 8th. Raymond James Financial started coverage on shares of CeriBell in a research note on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 target price for the company. TD Cowen restated a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. JPMorgan Chase & Co. decreased their price target on CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Finally, Canaccord Genuity Group increased their price objective on CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.67.

CeriBell Trading Down 0.5%

NASDAQ CBLL traded down $0.12 during trading hours on Wednesday, reaching $21.77. The company had a trading volume of 1,988 shares, compared to its average volume of 370,587. CeriBell has a 1-year low of $10.01 and a 1-year high of $26.04. The stock has a market capitalization of $807.67 million, a P/E ratio of -14.42 and a beta of 1.02. The stock has a 50-day moving average of $20.46 and a 200 day moving average of $15.42. The company has a current ratio of 12.65, a quick ratio of 12.25 and a debt-to-equity ratio of 0.12.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%.The business had revenue of $22.59 million during the quarter, compared to analysts’ expectations of $21.78 million. As a group, research analysts anticipate that CeriBell will post -2.46 earnings per share for the current fiscal year.

Insider Activity

In other CeriBell news, CTO Raymond Woo sold 11,112 shares of the stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $21.18, for a total transaction of $235,352.16. Following the completion of the sale, the chief technology officer directly owned 167,317 shares of the company’s stock, valued at approximately $3,543,774.06. This trade represents a 6.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP David Foehr sold 5,556 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $22.60, for a total value of $125,565.60. Following the sale, the vice president owned 18,900 shares of the company’s stock, valued at $427,140. This trade represents a 22.72% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 375,212 shares of company stock worth $7,306,950 over the last quarter. 20.10% of the stock is owned by insiders.

Hedge Funds Weigh In On CeriBell

Several hedge funds and other institutional investors have recently bought and sold shares of the company. CWM LLC increased its position in shares of CeriBell by 1,178.5% in the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after buying an additional 1,697 shares in the last quarter. Tower Research Capital LLC TRC increased its position in CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after purchasing an additional 1,801 shares in the last quarter. Ameritas Investment Partners Inc. raised its holdings in CeriBell by 97.5% in the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock valued at $48,000 after buying an additional 1,256 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in CeriBell during the third quarter worth approximately $33,000. Finally, Police & Firemen s Retirement System of New Jersey increased its position in shares of CeriBell by 161.0% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock worth $106,000 after acquiring an additional 3,502 shares in the last quarter.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.